Abstract: Prostacyclin (PGI.sub.2) analogs having a 6a-carba feature, for example a compound of the formula ##STR1## said analogs having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

Abstract: Prostacyclin (PGI.sub.2) analogs having a 6a-carba feature, for example a compound of the formula ##STR1## said analogs having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

Abstract: The present invention provides novel (11R)-11-deoxy-11-alkyl-6-oxo-prostaglandins which are useful for curing and preventing duodenal ulcers and for preventing or treating gastrointestinal cell damage caused by the use of other pharmacological agents.

Abstract: Prostaglandin analogs with the following cyclopentane ring structure: ##STR1## are disclosed along with intermediates useful in their preparation and processes for their preparation. These analogs are useful for the same pharmacological purposes as the prostaglandins, particularly and especially as blood platelet aggregation inhibitors.

Abstract: The present invention provides novel analogs of the thromboxanes. These thromboxane analogs are useful for a variety of pharmacologically useful purposes, most particularly as antithrombotic agents.

Abstract: The present invention relates to novel compositions of matter and particularly provides 9,11-dideoxy-10-oxa-TXB intermediates for preparing corresponding thromboxane analogs. These thromboxane analogs are useful for a variety of pharmacologically useful purposes, most particularly as anti-thrombotic agents.

Abstract: The present specification discloses novel 9,11-dideoxy- or 9,11,15-trideoxy-10-oxa-thromboxane B compounds, their novel method of preparation and the pharmaceutical compositions and use thereof as antihrombotic, antiinflammatory, and antiasthma agents.

Abstract: The present invention relates to novel 2-decarboxy-2-aminomethyl-6a-carba-PGI.sub.2 compounds, which are useful for inducing a variety of prostacyclin-like pharmacological effects. Accordingly, these compounds are useful pharmacological agents for the same purposes for which prostacyclin is employed.

Abstract: The present invention relates to two novel compounds, the pharmacologically acceptable salts thereof and their preparation and use as pharmacological agents. These novel compounds are11-deoxy-3,7-inter-m-phenylene-4,5,6-trinor-3-oxa-PGE.sub.1 and11-deoxy-3,7-inter-m-phenylene-4,5,6-trinor-3-oxa-13,14-dihydro-PGE.sub.1.

Abstract: Methylenecyclopentane derivatives, for example ##STR1## wherein R.sub.2 is a blocking group such as tetrahydropyranyl, and a process for preparing them; said derivatives having utility as prostaglandin intermediates.

Abstract: Methylenecyclopentane derivatives, for example ##STR1## wherein R.sub.2 is a blocking group such as tetrahydropyranyl, and a process for preparing them; said derivatives having utility as prostaglandin intermediates.

Abstract: Prostaglandin analogs with the following cyclopentane ring structure: ##STR1## are disclosed along with intermediates useful in their preparation and processes for their preparation. These analogs are useful for the same pharmacological purposes as the prostaglandins, particularly and especially as blood platelet aggregation inhibitors.

Abstract: Process for preparing bicyclic diols of the formula ##STR1## wherein C.sub.p H.sub.2p is a valence bond or alkylene of one to 4 carbon atoms, inclusive, with one or 2 carbon atoms in the chain between the phenylene ring and --O--; wherein Y is a hydrocarbyl or substituted hydrocarbly group; and wherein indicates attachment to the cyclopropane ring in exo or endo configuration. These diols and the intermediates prepared herein are useful intermediates in preparing prostaglandin analogs having pharmacological utility.

Abstract: Process for preparing bicyclic diols of the formula ##STR1## wherein C.sub.p H.sub.2p is a valence bond or alkylene of one to 4 carbon atoms, inclusive, with one or 2 carbon atoms in the chain between the phenylene ring and --0--; wherein Y is a hydrocarbyl or substituted hydrocarbyl group; and wherein .about. indicates attachment to the cyclopropane ring in exo or endo configuration. These diols and the intermediates prepared herein are useful intermediates in preparing prostaglandin analogs having pharmacological utility.

Abstract: Process for preparing bicyclic diols of the formula ##STR1## wherein C.sub.p H.sub.2p is a valence bond or alkylene of one to 4 carbon atoms, inclusive, with one or 2 carbon atoms in the chain between the phenylene ring and --O--; wherein Y is a hydrocarbyl or substituted hydrocarbyl group; and wherein .about. indicates attachment to the cyclopropane ring in exo or endo configuration. These diols and the tricyclic prostaglandin intermediates prepared herein are useful intermediates in preparing prostaglandin analogs having pharmacological utility.